Full List of Publications

P. Yolmo, S. Rahimi, S. Chenard, G. Consëil, D. Jenkins, K. Sachdeva, I. Emon, J. Hamilton, M. Xu, M. Rangachari, D. M. Berman, D. R. Siemens, M. Koti*. Atypical B cells promote cancer progression and poor response to Bacillus Calmette Guérin in non-muscle invasive bladder cancer (2024). Cancer Immunology Research. DOI: 10.1158/2326-6066.CIR-23-1114.​

​​

P. Yolmo, D. R. Siemens and M. Koti*. Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer. (2024). European Urology. DOI: 10.1016/j.eururo.2023.12.003.

​​

M. Koti* and D. R. Siemens. A step closer to predicting progression post BCG immunotherapy in high-risk non-muscle invasive bladder cancer. (2023). European Urology. doi: 10.1016/j.eururo.2023.06.017

​

M. Koti* and D. R. Siemens. Alvaro Morales; Giant in Urology. (2023). SIUJ.

​

M. Koti* and D. R. Siemens. The evolving landscape of bladder tertiary lymphoid structures. (2023). Journal of Urology (IF:7.6). DOI: 10.1097/JU.0000000000003530.

​

M. Koti*, T. Bivalacqua, P. C. Black, T. Cathomen, M. Galsky, J. L. Gulley, M. Ingersoll, A.M. Kamat, W. Kassouf, T. Powles, D. R. Siemens, J. Gao. Adaptive Immunity in Genitourinary Cancers. (2023). European Urology Oncology. DOI: https://doi.org/10.1016/j.euo.2023.03.002

​

N. Shakfa, D. Li, G. Conseil, E. Lightbody, J. Wilson-Sanchez, A. Hamade, S. Chenard, N. Jawa, B. Laight, A. Afriyie-Asante, K. Tyryshkin, M. Kobel, M. Koti*. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer. (2023). Journal of Immunotherapy for Cancer. DOI: 10.1136/jitc-2022-006170.

A. Hamade, D. Li, K. Tyrishkin, M. Xu, S. Chenard, G. Conseil, P. Yolmo, D.R. Siemens and M. Koti*. Age and sex associated differences in the murine urinary bladder influence the tumor immune microenvironment of a carcinogen induced model of bladder cancer. (2022). Biology of Sex Differences. DOI: 10.1186/s13293-022-00428-0 

 

N. Shakfa, D. Li, S. Nersesian, J. Wilson-Sanchez, M. Koti*. The STING pathway: therapeutic vulnerabilities in ovarian cancer. (2022). British Journal of Cancer. DOI: 10.1038/s41416-022- 01797-4.

 

M. Koti* and D.R. Siemens. Sex and gender differences in cancers of the genitourinary tract: the need to consider immune divergence. (2021). European Urology. DOI: https://doi.org/10.1016/j.eururo.2021.10.026

 

S. Chenard, C. Jackson, T. Vidotto, L. Chen, C. Hardy, T. Jamaspishvilli, D. Berman, D.R. Siemens and M. Koti*. Sexual dimorphism in outcomes of non-muscle invasive bladder cancer: a role of CD163+ macrophages, B cells and PD-L1 immune checkpoint. (2021). European Urology Open Science. DOI: https://doi.org/10.1016/j.euros.2021.05.002.

 

R. Sue-A-Quan, P.G. Patel, N. Shakfa, M.N. Nyi, A. Afriyie-Asante, E.Y. Kang, M. Köbel and Koti M*. Prognostic significance of T cells and tumour associated macrophages in clear cell carcinoma of the ovary. (2021). Gynecologic Oncology. DOI: 10.1016/j.ygyno.2021.05.010.

 

S. Chenard, D.R. Siemens and M Koti*. The CXCR3alt-CXCL11 axis in bladder cancer: potential for prediction of neoadjuvant chemotherapy response. (2021). Cellular and Molecular Immunology. DOI: 10.1038/s41423-021-00692-x.

 

C. Graham, J.-F. Paré, T. Cotechini, W. Hopman, C.C.T. Hindmarch, A. Ghaffari, D. Marginean, S. Chenard, M. Koti and D.R. Siemens. Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette- Guérin. (2021). Canadian Urologic Association Journal. DOI: 10.5489/cuaj.7066

 

A. Morales, D.R. Siemens and M. Koti. At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer. (2021). Urologic Oncology: Seminars and Original Investigations. DOI: 10.1016/j.urolonc.2020.10.009.

 

M. Koti, D.M. Berman, D.R. Siemens, D. Lange, E. Wang, P. Toren, B.J. Eigl, C. Hardy, R. Purves, V. Fradet, Y. Fradet, J. Mansure, W. Kassouf and P.C. Black; Canadian Bladder Cancer Research Network. Building a Canadian Translational Bladder Cancer Research Network. Canadian Urologic Association Journal. (2020) DOI: 10.5489/cuaj.6887.

 

N. Shakfa, D.R. Siemens and M. Koti*. Revisiting immunogenic cell death to improve treatment response in cancer. (2020). Chapter 4. Book: Biological Mechanisms and the advancing approaches to overcoming cancer drug resistance. ELSVIER.

 

M. Koti*, M.A. Ingersoll, S. Gupta., C. Lam, X. Li, A.M. Kamat, P.C. Black and D.R. Siemens. Sexual dimorphism in bladder cancer: implications for response to immunotherapy. (2020). European Urology: Oncology. DOI: https://doi.org/10.1016/j.euo.2020.08.013.

 

M. Koti*, A. Morales, C.H. Graham and D.R. Siemens. BCG Vaccine and COVID-19: Implications for Infection Prophylaxis and Cancer Immunotherapy. (2020). Journal for Immunotherapy of Cancer. Jul;8(2): e001119. DOI: 10.1136/jitc-2020-001119. 

 

T. Jamaspishvili, P.G. Patel, Y. Niu, T. Vidotto, I. Caven, R. Livergant, W. Fu, A. Kawashima, N. How, J.B. Okello, L.B. Guedes, V. Ouellet, C. Picanço, M. Koti, R.B. Reis, F. Saad, A.M. Mes-Masson, T.L. Lotan, J.A. Squire, Y.P. Peng, D.R. Siemens and D.M. Berman. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). (2020). Journal of National Cancer Institute. DOI: 10.1093/jnci/djaa032

 

T. Vidotto, C. Morais Melo, E. Castelli, M. Koti, R. Borges dos Reis and J.A. Squire. Emerging role of PTEN loss in evasion of the immune response to tumours. (2020) British Journal of Cancer. Apr 24. DOI: 10.1038/s41416-020-0834-6.

 

L.K. Symons, J.E. Miller, K. Tyryshkin, S.P. Monsanto, R.M. Marks, H. Lingegowda, K. Vanderbeck, T. Childs, S.L. Young, B.A. Lessey, M. Koti and C. Tayade. Neutrophil recruitment and function in endometriosis patients and syngeneic murine model. (2020) FASEB Journal. Jan;34(1):1558-1575

 

J.E. Miller, S.H. Ahn, R.M. Marks, S.P. Monsanto, A.T. Fazleabas, M. Koti and C. Tayade. IL-17 modulates peritoneal macrophage recruitment and M2 polarization in endometriosis. (2020) Frontiers in Immunology. Feb 14; 11:108

M. Koti, D.M. Berman, D.R. Siemens, D. Lange, E. Wang, P. Toren, B.J. Eigl, C. Hardy, R. Purves, V. Fradet, Y. Fradet, J. Mansure, W. Kassouf and P.C. Black; Canadian Bladder Cancer Research Network. Building a Canadian Translational Bladder Cancer Research Network. Canadian Urologic Association Journal. (2020) DOI: 10.5489/cuaj.6887.

 

N. Shakfa, D.R. Siemens and M. Koti*. Revisiting immunogenic cell death to improve treatment response in cancer. (2020). Chapter 4. Book: Biological Mechanisms and the advancig approaches to overcoming cancer drug resistance. ELSVIER.

 

M. Koti*, M.A. Ingersoll, S. Gupta., C. Lam, X. Li, A.M. Kamat, P.C. Black and D.R. Siemens. Sexual dimorphism in bladder cancer: implications for response to immunotherapy. (2020). European Urology: Oncology. DOI: https://doi.org/10.1016/j.euo.2020.08.013.

 

M. Koti*, A. Morales, C.H. Graham and D.R. Siemens. BCG Vaccine and COVID-19: Implications for Infection Prophylaxis and Cancer Immunotherapy. (2020). Journal for Immunotherapy of Cancer. Jul;8(2): e001119. DOI: 10.1136/jitc-2020-001119. Curriculum vitae Madhuri Koti 10 September, 2024

 

T. Jamaspishvili, P.G. Patel, Y. Niu, T. Vidotto, I. Caven, R. Livergant, W. Fu, A. Kawashima, N. How, J.B. Okello, L.B. Guedes, V. Ouellet, C. Picanço, M. Koti, R.B. Reis, F. Saad, A.M. Mes-Masson, T.L. Lotan, J.A. Squire, Y.P. Peng, D.R. Siemens and D.M. Berman. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). (2020). Journal of National Cancer Institute. DOI: 10.1093/jnci/djaa032

 

T. Vidotto, C. Morais Melo, E. Castelli, M. Koti, R. Borges dos Reis and J.A. Squire. Emerging role of PTEN loss in evasion of the immune response to tumours. (2020) British Journal of Cancer. Apr 24. DOI: 10.1038/s41416-020-0834-6.

 

L.K. Symons, J.E. Miller, K. Tyryshkin, S.P. Monsanto, R.M. Marks, H. Lingegowda, K. Vanderbeck, T. Childs, S.L. Young, B.A. Lessey, M. Koti and C. Tayade. Neutrophil recruitment and function in endometriosis patients and syngeneic murine model. (2020) FASEB Journal. Jan;34(1):1558-1575

 

J.E. Miller, S.H. Ahn, R.M. Marks, S.P. Monsanto, A.T. Fazleabas, M. Koti and C. Tayade. IL-17 modulates peritoneal macrophage recruitment and M2 polarization in endometriosis. (2020) Frontiers in Immunology. Feb 14; 11:108

 

S. Nersesian, N. Peterson, T. Vidotto, E. Lightbody, A. Afriyie-Asante, N. Shakfa, J. Francis and M. Koti*. Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer. (2019). bioRxiv. DOI: https://doi.org/10.1101/824094.

 

T. Vidotto, S. Nersesian, C.H. Graham, D.R. Siemens and M. Koti*. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. (2019). Journal for Immunotherapy of Cancer. Jun 7;7(1):148.

 

M. Koti*, S. Chenard, S. Nersesian, T. Vidotto, A. Morales and D.R. Siemens. Investigating the STING pathway to explain mechanisms for BCG failures in non-muscle invasive bladder cancer: prognostic and therapeutic implications (2019). Bladder Cancer. DOI: 10.3233/BLC-190228.

 

N. Vitkin, S. Nersesian, D.R. Siemens and M. Koti*. The immune contexture of prostate cancer. (2019). Frontiers in Immunology. March 28 (10):603.

 

T. Vidotto, F.P. Saggioro, T. Jamaspishvili, D.L. Chesca, C.G. Picanço de Albuquerque, R.B. Reis, C.H. Graham, D.M. Berman, D.R. Siemens, J.A. Squire and M. Koti*. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. (2019). The Prostate. Jun;79(9):969-979.

 

C.G. Picanço de Albuquerque, T. Vidotto, C.S. Pereira, F.P. Saggioro, T. Jamaspishvili, M. Koti, D.M. Berman, J.A. Squire and R.B. Reis. PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features. (2019). Applied Cancer Research. https://doi.org/10.1186/s41241-018-0071-y

 

K. Khalaj, J.E. Miller, H. Lingegowda, A.T. Fazleabas, S.L. Young, B.A. Lessey, M. Koti and C. Tayade. Extracellular vesicle from endometriosis patients are characterized by unique miRNA LNC RNA signature. (2019) JCI Insight Sep 19;4(18): e128846.

 

D.R. Siemens and M. Koti*. Diversifying our research portfolio: A conversation with an early career investigator. (2018). Can Urol Assoc J. Aug;12(8):223-224.

 

A. Yu, J.J. Mansure, S. Solanki, D.R. Siemens, M. Koti, A.B.T. Dias, M.M. Burnier, F. Brimo and W. Kassouf. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. (2018). PLoS One. Oct 11;13(10): e0205746.

 

A. Ghaffari, N. Peterson, K. Khalaj, N. Vitkin, A. Robinson, J.A. Francis and M. Koti*. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. (2018). British Journal of Cancer (IF:8.3). Aug;119(4):440-449.

 

C. Clifford, N. Vitkin, S. Nersesian, G. Reid-Schachter, J.-A. Francis and M. Koti*. Multi-omics in high-grade serous ovarian cancer: biomarkers from genome to the immunome. (2018). American Journal of Reproductive Immunology. Aug;80(2): e12975. Featured on Cover.

 

L.K. Symons, J.E. Miller, V.R. Kay, R.M. Marks, K. Liblik, M Koti and C. Tayade. The immunopathophysiology of Endometriosis. (2018). Trends Mol Med. Sep;24(9):748-762.

 

J.A. Josahkian, F.P. Saggioro, T. Vidotto, H.T. Ventura, F.J. Candido Dos Reis, C.B. de Sousa, D.G. Tiezzi, J.M. de Andrade, M. Koti and J.A. Squire. Increased STAT1 expression in high grade serous ovarian cancer is associated with a better outcome. (2018). Int J Gynecol Cancer. Mar;28(3):459-465.

 

M. Koti*, A.S. Xu, K.Y.M. Ren, K. Visram, R. Ren, D. Berman and D.R. Siemens. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. (2017). Bladder Cancer. 3(4):259-267.

 

K.K. Au, N. Peterson, P. Truesdell, G. Reid-Schachter, K. Khalaj, R. Ren, J.-A. Francis, C.H. Graham, A.W. Craig and M. Koti*. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. (2017). Gynecologic Oncology (IF: 5.3). 145(3):436-445.

 

R. Ren, K. Tyrishkin, C.H. Graham, M. Koti and D.R. Siemens. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. (2017). Oncotarget. 8(41):70982-71001.

 

M. Bidarimath, K. Khalaj, R.T. Kridli, F.W.K. Kan, M. Koti and C. Tayade. Extracellular vesicle mediated intercellular communication at the porcine maternal-fetal interface: A new paradigm for conceptus-endometrial cross-talk. (2017). Scientific Reports. 7:40476.

 

K. Khalaj, J.E. Miller, C.R. Fenn, S. Ahn, R.L. Luna, L. Symons, S.P. Monsanto, M. Koti and C. Tayade. RNA binding proteins in female reproductive pathologies. (2017). American Journal of Pathology. 187(6):1200-1210.

 

K. Khalaj, S. Ahn, M. Bidarimath, Y. Nasirzadeh, S. Singh, A.T. Fazleabas, S.L. Young, B.A. Lessey, M. Koti* and C. Tayade*. A balancing act: RNA binding protein HuR/TTP axis in endometriosis patients. (2017). Scientific Reports. 7(1):5883.

K.K. Au, C. Le Page, R. Ren, L. Meunier, I. Clément, K. Tryshkin, N. Peterson, J. Kendal; Dupont, T. Childs, J.-A. Francis, C.H. Graham, A.W. Craig, J.A. Squire, A.-M. Mes-Masson and M. Koti*. STAT1 induced intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. (2016). Journal of Pathology: Clinical Research (IF: 4.3). 2(4):259-270.

 

R. Ren, M. Koti, T. Hamilton, C.H. Graham, J.G. Nayak, J. Singh, D.E. Drachenberg and D.R. Siemens. A primer on tumour immunology and prostate cancer immunotherapy. (2016). Can Urol Assoc J. 10(1-2):60-5.

 

S.H. Ahn, K. Khalaj, S.L. Young, B.A. Lessey, M. Koti and C. Tayade. Immune-inflammation gene signatures in endometriosis patients. (2016). Fertil Steril. 106(6):1420-1431.e7.

 

M. Bidarimath, K. Khalaj, R.T. Kridli, J.M. Wessels, M. Koti and C. Tayade. Altered expression of chemokines and their receptors at porcine maternal-fetal interface during early and mid gestational fetal loss. (2016). Cell Tissue Res. 366(3):747-761.

 

M. Black, I.B. Barsoum, P. Truesdell, T. Cotechini, S.K. Macdonald-Goodfellow, M. Petroff, D.R. Siemens, M. Koti, A.W. Craig and C.H. Graham. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. (2016). Oncotarget. 7(9):10557-67.

 

K.K. Au, J.A. Josahikan, J.-A. Francis, J.A. Squire and M. Koti*. Current state of biomarkers in ovarian cancer prognosis. (2015). Future Oncology. 11(23): 3187-95.

 

M. Koti*, A. Siu, I. Clément, M. Bidarimath, G. Turashvilli, A. Edwards, K. Rahimi, A.-M. Mes Masson and J.A. Squire. A distinct pre-existing inflammatory tumor microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. (2015). British Journal of Cancer (IF: 8.3). 113(12):1746.

 

I.B. Barsoum, M. Koti, D.R. Siemens and C.H. Graham. Mechanisms of hypoxia-mediated immune escape in cancer. (2014). Cancer Research. 74(24):7185-90.

 

M. Koti, S.S. Saini, A. Sachan and A.K. Kaushik. Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines. (2014). Antibodies. 3:205-214. 

 

J.W. Martin, S. Chilton-MacNeill, M. Koti, A.J. van Wijen, J.A. Squire and M. Zielenska. Digital expression profiling identifies FOS and RECQL4 as potential oncogenes in a cohort of pediatric osteosarcoma tumours. (2014). PLoS One. 9(5): e95843.

 

J. Geraci, M. Dharsee, P. Nuin, A. Haslehurst, M. Koti, H.E. Feilotter and K. Evans. Exploring high dimensional data with Butterfly: a novel clustering algorithm based on discrete dynamical systems. (2014). Bioinformatics. 30(5):712-8.  13:549.

​

​